Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foscelantan for Diabetic Foot and Venous Insufficiency Wounds
NCT06232421Phase 3Not yet recruiting
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Implantable Devices
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of foscelantan in diabetic foot ulcer (DFU) and venous leg ulcer (VLU) (4 arms). Primary endpoint: Number of patients with trophic ulcers cured at 15 days. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
foscelantan
03
Conditions
diabetic foot ulcer (DFU)venous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT06232421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232421.